Preclinical assessment of a diuretic agent is straightforward with dual goals of identifying the active substance and its site of activity. In addition, one must determine whether the diuretic gains access to its site of action from the blood as opposed to the urine, and depending upon those findings, assess mechanisms by which access to the active site occurs. Both in vivo and in vitro studies are required to assess the specific nephron segment at which the diuretic has activity. These studies are important for predictions as to efficacy and side effects. Knowledge that a diuretic has its effects at a particular nephron site allows prediction of the degree of natriuresis that will occur and also the concomitant excretion of other electrolytes which may impact on adverse effects (e.g., potassium or magnesium).


Proximal Tubule Fractional Excretion Nephron Segment Diuretic Agent Free Water Clearance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Chennavasin, P., R. Seiwell, D. C. Brater, and W. M. M. Liang (1979). Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int., 16, 187–195.PubMedCrossRefGoogle Scholar
  2. Dal Canton, A., D. Russo, R. Gallo, G. Conte, and V. E. Andreucci (1981). Muzolimine: a high-ceiling diuretic suitable for patients with advanced renal failure. Br. Med. J. 282, 595–598.CrossRefGoogle Scholar
  3. Faedda, R. S., G. F. Branca, B. Contu, and E. Bartoli (1985). Demonstration of action of muzolimine on the serosal side of the Henle’s loop cells. Z. Kardiol. 74 (suppl 2), 166–170.Google Scholar
  4. Graven, J., and B. Kolling (1983). Effects of muzolimine in microperfusion studies of loops of Henle in rats. In V. E. Andreucci (Ed.), Recent Advances in Diuretic Therapy. Excerpta Medica, Amsterdam. pp. 37–45.Google Scholar
  5. Greger, R., and E. Schlatter (1983). Cellular mechanism of the action of loop diuretics on the hick ascending limb of Henle’s loop. Klin. Worchenschr. 61, 1019–1027.CrossRefGoogle Scholar
  6. Kirchner, K. A. (1987). Lithium as a marker for proximal tubular delivery during low salt intake and diuretic infusion. Am. J. Physiol., 253 F188- F196.Google Scholar
  7. Koomans, H. A., W. H. Boer, and E. J. D. Mees (1989). Evaluation of lithium clearance as a marker of proximal tubule sodium handling. Kidney Int. 36, 2–12.Google Scholar
  8. Odlind B. (1979). Relationship between tubular secretion of furosemide and its saluretic effect. J. Pharmacol. Exp. Ther. 208, 515–521.PubMedGoogle Scholar
  9. Odlind, B., and B. Beermann (1980). Renal tubular secretion and effects of furosemide. Clin. Pharmacol. Ther. 27, 784–790.Google Scholar
  10. Rosin, J. M., M. A. Katz, F. C. Rector, and D. W. Seldin (1970). Acetazolamide in studying sodium reabsorption in diluting segment. Am. J. Physiol. 219, 1731–1738.PubMedGoogle Scholar
  11. Seldin, D. W., and F. C. Rector (1973). Evaluation of clearance methods for localization of site of action of diuretics. In A. F. Lant and G. M. Wilson (Eds.), Modern Diuretic Therapy in the Treatment of Cardiovascular and Renal Disease. Excerpta Medica, Amsterdam. pp. 97–111.Google Scholar
  12. Thomsen, T., M. Schou, I. Steiness, and H. E. Hansen (1969). Lithium as an indicator of proximal sodium reabsorption. Pflügers Arch., 308 180–184.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • D. Craig Brater
    • 1
  1. 1.Department of Medicine Clinical Pharmacology DivisionIndiana University School of MedicineIndianapolisUSA

Personalised recommendations